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Transcriptional intermediary factor 1 (TIF1;
alias, TRIM33/RFG7/PTC7/ectodermin) belongs to
an evolutionarily conserved family of nuclear fac-
tors that have been implicated in stem cell pluripo-
tency, embryonic development, and tumor suppres-
sion. TIF1 expression is markedly down-regulated
in human pancreatic tumors, and Pdx1-driven Tif1
inactivation cooperates with the KrasG12D onco-
gene in the mouse pancreas to induce intraductal
papillary mucinous neoplasms. In this study, we
report that aged Pdx1-Cre; LSL-KrasG12D; Tif1 lox/lox
mice develop pancreatic ductal adenocarcinomas
(PDACs), an aggressive and always fatal neoplasm,
demonstrating a Tif1 tumor-suppressive function
in the development of pancreatic carcinogenesis.
Deletion of SMAD4/DPC4 (deleted in pancreatic car-
2214cinoma locus 4) occurs in approximately 50% of
human cases of PDAC. We, therefore, assessed the
genetic relationship between Tif1 and Smad4 sig-
naling in pancreatic tumors and found that Pdx1-
Cre; LSL-KrasG12D; Smad4lox/lox; Tif1 lox/lox (alias,
KSSTT) mutant mice exhibit accelerated tumor pro-
gression. Consequently, Tif1 tumor-suppressor effects
during progression from a premalignant to a malignant
state in our mouse model of pancreatic cancer are inde-
pendent of Smad4. These findings establish, for the first
time to our knowledge, that Tif1 and Smad4 both reg-
ulate an intraductal papillary mucinous neoplasm-to-
PDAC sequence through distinct tumor-suppressor
programs. (Am J Pathol 2012, 180:2214–2221; http://dx.doi.
org/10.1016/j.ajpath.2012.02.006)
Transcriptional intermediary factor 1 (TIF1; alias,
TRIM33/RFG7/PTC7/ectodermin) belongs to an evolu-
tionarily conserved family of nuclear factors that have
been implicated in stem cell pluripotency, embryonic de-
velopment, and tumor suppression.1 These proteins are
characterized by the presence of a RING domain with E3
ubiquitin-ligase activity and multiple chromatin interac-
tion domains, including B-boxes, coiled-coil domains,
plant homeo domains, and bromodomains, suggesting
functions in both protein degradation and modulation of
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AJP June 2012, Vol. 180, No. 6transcription. TIF1 interacts with transforming growth
factor  (TGF-) signaling SMAD transcription factors.2–5
Overall, the potential role of TIF1 in the TGF-–SMAD
signaling pathway is of high significance given the im-
portance of this pathway in tumor suppression. TGF- is
a secreted polypeptide belonging to a wide family of
cytokines and growth factors, including TGF-s, bone
morphogenetic proteins, and activins. TGF- signaling
involves two serine-threonine kinase receptors, type I and
II TGF- receptors. After binding to its receptors, TGF-
induces the phosphorylation of the type I TGF- receptor,
whose serine-threonine enzymatic activity is activated to
allow the phosphorylation of receptor-regulated SMAD2
and SMAD3 (R-SMADs). Phosphorylated R-SMADs then
interact with SMAD4. The R-SMADs–SMAD4 complex ac-
cumulates within the nucleus, binds to DNA, and acti-
vates the transcription of target genes. TGF- also acti-
vates noncanonical pathways that are independent of
SMAD proteins.
Pancreatic cancer is a particularly relevant context for
exploring the interplay of TIF1 and TGF-–SMAD func-
tion because this malignancy is characterized by a high
rate of inactivating genetic alterations in the TGF-–
SMAD4 pathway. Pancreatic ductal adenocarcinoma
(PDAC) is an aggressive neoplasm; it is always fatal and
is the fifth most common cause of death by cancer in the
Western world. The median age of patients diagnosed as
having PDAC is 65 to 70 years. PDAC, which affects the
exocrine pancreas, accounts for 80% of pancreatic
cancers. PDAC arises from precursor lesions with ductal
differentiated features. The precursors of the disease are
divided into three groups: pancreatic intraepithelial neo-
plasm, intraductal papillary mucinous neoplasm (IPMN),
and mucinous cystic neoplasm. Both human patients and
mouse models with these types of lesions have an in-
Figure 1. Tif1 deficiency cooperates with KrasG12D to drive an IPMN-PDAC
sequence. A: Longitudinal magnetic resonance imaging study (from 140 to 230
days) of a KTT mouse. Cystic lesions (hypersignal, arrow) and a firm mass
(isosignal, dotted line) are indicated. B: Macroscopic analysis of the KTT
pancreas after dissection at 230 days. Dotted line, PDAC; arrows, IPMN le-
sions. C: Histological section of the KTT pancreas stained with hematoxylin-
phloxin-saffron. The dotted line separates PDAC from the IPMN environment.creased risk of developing a PDAC.We previously developed a genetically engineered mouse
model and showed that targeted pancreatic conditional inac-
tivation of Tif1 cooperated with activated Kras to induce
IPMNs.6 Indeed, Pdx1-Cre; LSL-KrasG12D; Tif1 lox/lox mice
(KTT) develop IPMNs with a short latency and a full pen-
etrance (n  12; age range, 19 to 189 days). However,
none of these KTT mice presented obvious signs of ma-
lignant transformation reminiscent of PDAC.
In the present study, we explored the susceptibility of
KTT aging mice (aged 200 days) to develop PDAC. We
also investigated the impact of Smad4 deletion, which
occurs in approximately 50% of human PDACs, in the
IPMN-PDAC sequence resulting from combined Kras ac-
tivation and Tif1 deficiency in the murine pancreas.
Materials and Methods
Mice
Tif1 lox/lox,7 LSL-KrasG12D,8 Smad4lox/lox,9 and Pdx1-
Cre10 alleles, provided by other groups, were previously
described. Mice were maintained in a specific pathogen-
free animal facility at the AniCan Plateform, Centre Léon
Bérard (Lyon, France), and handled in compliance with
the institutional guidelines. All procedures were ap-
proved by an ethics committee under governmental reg-
ulatory authority (Comité d’Evaluation Commun au Centre
Léon Bérard, à l’Animalerie de transit de l’ENS, au PBES
et au laboratoire P4).
Histological Data
Histological experiments were performed as previously
described.6 The primary antibodies used are: mouse
monoclonal antibodies against Tif1 (1:500; Euromedex,
Souffelweyersheim, France), Mucin-5ac (clone 45M1,
1:100; Thermo Scientific, Illkirch, France), chymotrypsin
(1:1000; AbD Serotec, Colmar, France), E-cadherin
(1:700; BD Biosciences, Le Pont-De-Claix, France), and
proliferating cell nuclear antigen (1:100; Santa Cruz Bio-
technology, Santa Cruz, CA); rat monoclonal antibodies
against cytokeratin-19 (1:50, Troma-III-s; Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City,
IA) and F4/80 (1:100; Acris Antibodies, Herford, Ger-
many); goat polyclonal antibodies against vimentin
(1:100; Santa Cruz Biotechnology); and guinea pig poly-
clonal antibodies against -smooth muscle actin (-SMA,
1:100; DakoCytomation, Trappes, France). For immuno-
fluorescence, histological section cells were incubated
with rabbit polyclonal anti-Glut2 antibody (1:100; Milli-
pore, Molsheim, France) and, finally, with secondary-la-
beled antibody (goat anti-rabbit-IgG Alexa Fluor 488 nm,
1:200; Invitrogen, Cergy-Pontoise, France). Alcian blue
staining was performed in acidic pH conditions.
Magnetic Resonance Imaging
The magnetic resonance imaging experiments were per-
formed as previously described.6
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Statistical analyses were performed using the Fisher
exact test. Differences were considered significant
Figure 2. Histological characterization of KTT pancreatic tumors. IHC an
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E-cadherin (I) from membrane toward the inside cellular compartment.when P  0.05.Results
We generated aging KTT mice that were euthanized be-
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eveals a complete loss of Tif1 expression in the epithelial compartment
motrypsin, B) and ductal (cytokeratin-19, C) compartments. Markers of
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n  9) or Pdx1-Cre; Tif1 lox/lox (TT; n  6) control mice
developed PDAC during this time frame (see Supplemen-
tal Table S1 at http://ajp.amjpathol.org). The longitudinal
analysis of one KTT mouse by magnetic resonance im-
aging showed gradual growth of cystic lesions (hyper-
signal), with the onset at 200 days of age of a firm and
Figure 3. Deletion of Smad4 in KTT mice accelerates PDAC development. H
hematoxylin-phloxinsaffron from 25 to 125 days. For each panel pair, low (uppe
developing PDACs before the age of 200 days is represented as a fraction numbersolid mass (isosignal) that developed into the tail of thepancreas (Figure 1A). Thirty days later (at the age of 230
days), the size of this solid lump had dramatically in-
creased, prompting us to euthanize the animal. Macro-
scopic analysis of the pancreas from this animal con-
firmed the presence of multifocal cystic lesions (smooth
texture), colonizing the entire organ, and the presence of
a voluminous and firm tumor (tough texture), which had
al sections of K, KTT, and KSSTT mutant mouse pancreas were stained with
igh (lower) magnifications are shown. For each genotype, the number of mice
theses). The P value was determined by the exact Fisher test. *P  0.05.istologicinvaded the tail of the pancreas (Figure 1B). Microscopic
hemato
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KTT mouse revealed a poorly differentiated carcinoma
(Figure 1C), found adjacent to epithelial cysts reminis-
cent to human IPMNs. We observed focal destruction of
the pancreatic parenchyma by a malignant epithelial pro-
liferation made of irregular glands and cellular cords.
Tumor cells are irregular in size and shape, with abun-
dant basophilic cytoplasms and irregular nuclei. Mitotic
features are common. The tumoral stroma presents with
multiple inflammatory cells but only a low level of collagen
between tumor cells. Histological analysis of the two
other KTT mice sacrificed at the ages of 256 and 342
days revealed the presence of a small focus with PDAC
and the presence of multiple large high-grade IPMNs
with some papillary protrusions (data not shown). Alto-
gether, these data indicate that KTT mice develop IPMNs
with short latency and revealed that these tumors have
Figure 4. KTT and KSSTT pancreatic tumors display different histolo
231-day-old KTT, and 126-day-old KSSTT pancreas samples stained with
for Mucin-5ac (Muc5ac), vimentin, or E-cadherin.high malignant potential.To carefully characterize the pathological features of
PDAC arising in KTT mice, we performed immunohisto-
chemistry (IHC) and immunohistofluorescence experi-
ments, which allowed us to underline the hallmarks of
PDAC (Figure 2). In accordance with the expression pat-
tern of the Pdx1-Cre transgene (in all pancreatic epithelial
lineages10), we observed a complete loss of Tif1 ex-
pression in the epithelial compartment of KTT tumors,
whereas residual expression could be detected in the
microenvironment surrounding the cancer cells (mesen-
chymal cells and immune infiltrates) (Figure 2A). KTT
tumors have lost their acinar differentiation (chymotrypsin
negative) (Figure 2B). Cytokeratin 19, a marker that is
normally only expressed at the membrane of the cells
lining the duct in wild-type pancreas, presents a faint, but
diffuse, cytoplasmic localization in KTT tumors, attesting
to the altered ductal differentiation of these tumors (Fig-
atures. Histological sections of 365-day-old control [wild type (WT)],
xylin-phloxinsaffron or Alcian blue (mucin specific) or subjected to IHCgical feure 2C). We next explored the tumor-associated stroma.
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by an abundant stroma (desmoplastic stroma), the epi-
thelial cancer cells eventually representing 10% of the
tumor. Positive staining for vimentin (Figure 2D) and
-SMA (Figure 2E) confirmed the presence of a fibroblas-
tic/myofibroblastic stromal compartment in KTT tumors.
Interestingly, some vimentin-positive cells (but -SMA
negative) were seen lining the lumen, suggesting that
some tumoral cells express the vimentin marker. We also
detected tumor-associated macrophages (F4/80-positive
cells) in KTT tumors (Figure 2F). To assess the prolifera-
tive index and the metabolic status of KTT tumors, we
examined the expression of proliferating cell nuclear an-
tigen (Figure 2G) and glut2 (Figure 2H) markers, which
are both highly expressed in KTT tumors. The poorly
differentiated state is generally associated with disorga-
nization of E-cadherin, a membrane protein ensuring the
maintenance of proper cell-cell contact. IHC against E-
cadherin in KTT PDACs revealed a severe disorganiza-
tion of the epithelial architecture, with a clear delocaliza-
tion of E-cadherin from the membrane to the intracellular
compartment (Figure 2I).
SMAD4 (alias, DPC4, deleted in pancreatic carcinoma,
locus 4) is involved in TGF- signaling and is a major
tumor suppressor deleted in approximately 50% of
PDACs. TIF1 has been implicated as a modulator of
TGF- signaling, potentially either augmenting or com-
promising SMAD protein function. To examine the ge-
netic interactions between Tif1 and Smad4, we gener-
ated conditional null mice for both Smad4 and Tif1 in a
Kras-driven mouse model of pancreatic cancer. We ob-
served that Pdx1-Cre; Smad4lox/lox; Tif1 lox/lox (SSTT;
n  18) double-null mice do not develop pancreatic
lesions (all ages, n  18; aged 125 days, n  8) (see
Supplemental Table S1 at http://ajp.amjpathol.org). We
next generated Pdx1-Cre; LSL-KrasG12D; Smad4lox/lox;
Tif1 lox/lox mice harboring pancreatic inactivation for both
Smad4 and Tif1 in a KrasG12D background (KSSTT; n 
9) (see Supplemental Table S1 at http://ajp.amjpathol-
.org). Interestingly, the two KSSTT mice that we eutha-
nized at the age of 25 days presented high-grade IPMN
lesions. Moreover, 44% (4/9) of KSSTT mice that we eu-
thanized before the age of 200 days had developed a
PDAC (Figure 3). More important, PDAC developing as
soon as the age of 46 days has never been reported in K
or KTT mice. Thus, double-null homozygous inactivation
of Tif1 and Smad4, in a KrasG12D background, induces
the formation of PDACs at a higher frequency and a
shorter latency than any other combined mutations. We
have also generated Pdx1-Cre; LSL-KrasG12D;
Smad4lox/; Tif1 lox/loxmice (KSTT; n 7) harboring Tif1
homozygous inactivation and a Smad4 heterozygous in-
activation. Interestingly, 50% (4/7) of the KSTT mice
develop PDACs in an intermediary time frame to what is
observed in KTT and KSSTT mice (see Supplemental
Table S1 at http://ajp.amjpathol.org).
Histological analysis of these tumors revealed that KSSTT
tumors retained more differentiated features compared with
KTT tumors. Indeed, KSSTT showed strong Alcian blue
staining and Mucin-5ac immunoreactivity, attesting a well-
differentiated mucinous phenotype. In addition, KSSTT tu-mors retained a clear epithelial differentiation, as attested
by an intact E-cadherin intercellular network and the ab-
sence of vimentin expression (Figure 4).
Discussion
By using the Pdx1-Cre; LSL-KrasG12D; Tif1 lox/lox mouse
model, we previously reported that the inactivation of Tif1
could cooperate with the KrasG12D oncogene to induce
IPMNs with full penetrance by the age of 189 days.6 Herein,
we extended this study by demonstrating, in aging KTT
mice (aged 200 days), that homozygous inactivation of
Tif1 significantly potentiates the capacity of KrasG12D to
induce PDACs, supporting the potency of IPMNs to
evolve toward aggressive lesions, as observed in hu-
mans. This observation reinforces the existence of a
tumor-suppressive pathway, orchestrated by Tif1, to
prevent malignant transformation of premalignant le-
sions induced by activated Kras. However, no direct
communication between the tumor itself and a pre-
existing IPMN was proved by the pathological exami-
nation. Whether PDACs directly arise from existing pre-
cancerous cystic lesions remains an open question in
the field.
The mechanism by which TIF1 exerts its tumor-sup-
pressive effect remains elusive. TGF- signaling is clas-
sically considered as tumor suppressive, via its anti-pro-
liferative and pro-apoptotic functions, to prevent normal
or premalignant cells to evolve toward a malignant state.
This is well illustrated by the high rate of inactivating
genetic alterations in the TGF-–SMAD4 pathway11 and
by mouse models showing that Smad4-homozygous in-
activation, in combination with activated Kras,12–14
causes the development of cystic lesions with a higher
potential to progress toward PDAC, compared with mice
expressing activated Kras alone (Pdx1-Cre; LSL-
KrasG12D).15 To address the genetic relationship between
Tif1 and Smad4 in pancreatic tumors, we generated
KSSTT double-null homozygous mutant mice. We ob-
served a pronounced genetic interaction between Smad4
and Tif1 inactivation, demonstrating that both molecules
act in separate pathways to suppress a premalignant-to-
malignant Kras-driven pancreatic tumor. It is, however,
possible that the capacity of Tif1 to constrain the pre-
malignant-to-malignant progression depends on the
modulation of TGF- signaling arms independent of
SMAD4. This could involve R-SMADs or noncanonical
TGF- pathways. Indeed, it has been proposed in
other cell systems that TIF1/R-SMAD complexes
could positively mediate TGF- functions,3,16,17
through the regulation of expression of a different set of
genes by R-SMAD–TIF1 and R-SMAD–SMAD4 com-
plexes.18 This hypothesis is consistent with the pheno-
type observed in Pdx1-Cre; LSL-KrasG12D; TRII lox/lox
mice,19 in which canonical and noncanonical TGF-
pathways are abrogated, with a phenotype resembling
the one observed in KSSTT mice. Finally, TIF1 could
prevent the premalignant-to-malignant progression
through mechanisms totally unrelated to TGF- signal-
ing. Indeed, it may result from the modulation of gen-
2220 Vincent et al
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For instance, TIF1 and related family member TIF1
were involved in chromatin remodeling20 and tran-
scription elongation,17,21 and TIF1 was involved in
DNA repair.22
Once the malignant transformation has occurred by by-
passing its anti-proliferative and pro-apoptotic effects,
TGF- acquires oncogenic properties and eventually facil-
itates tumor progression. Even if our results clearly argue for
a role of Tif1 to constrain the transition between a prema-
lignant and a malignant state through a mechanism inde-
pendent of Smad4 activity, we cannot exclude that Smad4
function may facilitate tumor aggressiveness after the pre-
malignant state is overrun and the premalignant state is
achieved (in malignant tumors that retained a functional
Smad4). In such cases, Smad4 may facilitate local invasion
andmetastatic dissemination by inducing epithelial-to-mes-
enchymal transition (EMT). This may reflect the capacity of
TIF1 to constrain invasiveness programs, such as EMT, as
recently demonstrated in vitro in human mammary epithelial
cells.18 Consistent with this, the Pdx1-Cre; LSL-KrasG12D;
Ink4a/Arf lox/lox; Smad4lox/lox mice12 develop well-differenti-
ated PDAC, with attenuated invasive properties, compared
with the poorly differentiated tumors observed in Pdx1-Cre;
LSL-KrasG12D; Ink4a/Arf lox/lox mice. In our study, even if
PDACs developing in KSSTT mice arise with a shorter la-
tency and a higher penetrance compared with KTT mice,
they present a well-differentiated phenotype compared with
the poorly differentiated phenotype of the PDACs we ob-
served in KTTmice. This suggests a tumor-suppressive role
of Tif1 to limit the aggressiveness of Smad4-positive can-
cer cells by compromising their capacity to undergo EMT. It
may result in a lower capacity to generate metastases. The
molecular mechanism occurring in vivo may rely on the
capacity of TIF1 to mono-ubiquitinate SMAD4 and limit
SMAD4 nuclear accumulation, as demonstrated in other
systems.2,4
In conclusion, we demonstrate, in this study, that Tif1
inactivation cooperates with activated Kras to potentiate the
premalignant-to-malignant transition to promote the onset of
poorly differentiated tumors. We also evidence that the
tumor-suppressive role of Tif1 during the premalig-
nant-to-malignant progression is independent of
Smad4 activity. Finally, we noticed that the absence of
Smad4 could redirect Tif1-negative pancreatic tu-
mors toward a well-differentiated phenotype, consis-
tent with an effect of Tif1 to inhibit Smad4-dependent
EMT. Then, Tif1 exerts tumor-suppressive functions
independently of Smad4 in the premalignant-to-malig-
nant transition but may also exert tumor-suppressive
functions dependent on Smad4 later on during tumor
progression.
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